Results 11 to 20 of about 27,150 (219)
Frontiers in Pediatrics, 2022 ObjectiveThe study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in children (MIS-C).MethodsThis is a cross-sectional retrospective study consisting of pediatric patients
Şengül Çaǧlayan +12 more
doaj +1 more source
Effect of anakinra in COVID-19 [PDF]
The Lancet Rheumatology, 2020 Contains fulltext : 225435.pdf (Publisher’s version ) (Closed access)
Kooistra, Emma J +3 more
openaire +4 more sources
Pediatric Rheumatology Online Journal, 2023 Background The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids.
Esra B. Akkoyun +7 more
doaj +1 more source
The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats
Brazilian Journal of Pharmaceutical Sciences, 2023 Acrylamide is a neurotoxic compound. Moreover, anakinra is an interleukin-1 (IL-1) receptor antagonist used in rheumatoid arthritis treatment. This study investigated the effect of anakinra on acrylamide-related neuropathy and neuropathic pain ...
Alevtina Ersoy +5 more
doaj +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Hepatology, EarlyView., 2022 Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background ST‐segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade with anakinra significantly reduced the area under the curve for hsCRP ...
Antonio Abbate +28 more
doaj +1 more source
Anakinra treatment for refractory cerebral autoinflammatory responses
Annals of Clinical and Translational Neurology, 2022 Refractory cerebral autoinflammatory–autoimmune diseases are often associated with dysregulated innate immunity and are targeted by anakinra, an interleukin‐1 receptor antagonist.
Yoonhyuk Jang +5 more
doaj +1 more source
PLoS ONE, 2023 BackgroundIn patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death.
Francesco Vladimiro Segala +8 more
doaj +1 more source
Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis
Critical Care Explorations, 2023 OBJECTIVES:. Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required.
Samuel D.J. Dubinsky, PharmD +7 more
doaj +1 more source
Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. [PDF]
PLoS ONE, 2013 IL-1 receptor antagonist anakinra is usually highly efficient in Schnitzler syndrome (SS), a rare inflammatory condition associating urticaria, fever, and IgM monoclonal gammopathy.
David Launay +9 more
doaj +1 more source